MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
DURECT Corporation EBITDA 2011-2026 | DRRX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.9 M | -35 M | -34 M | -12.3 M | -18.9 M | -23.4 M | -1.8 M | -31.9 M | -20.2 M | -20.4 M | -20.6 M | 17 M | -17.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17 M | -36.9 M | -19.7 M |
Quarterly EBITDA DURECT Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -4.07 M | - | - | -6.25 M | - | - | -11 M | - | -2.02 M | -11.1 M | -10.3 M | - | -9.37 M | -8.66 M | -9.62 M | - | -8.61 M | 14.5 M | -9.76 M | - | -1.49 M | -6.62 M | -6.63 M | - | -2.13 M | -6.39 M | -7.72 M | - | 6.46 M | -9.14 M | -7.46 M | - | -7.98 M | -8.29 M | -7.22 M | - | -5.63 M | -4.68 M | -4.28 M | - | -6.13 M | -5.14 M | -3.45 M | - | -5.34 M | -4.64 M | -4.94 M | - | -4.12 M | -3.92 M | 31 M | - | -4.28 M | -4.77 M | -6.11 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 31 M | -11.1 M | -4.55 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.29 | -0.6 % | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
-1.97 M | $ 0.63 | 0.3 % | $ 11 M |  China |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
-176 M | $ 2.51 | -0.33 % | $ 1.31 B | Canada |
 |
Emergent BioSolutions
EBS
|
-601 M | $ 7.98 | -0.87 % | $ 409 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 3.05 | - | $ 42.9 M | USA |
 |
Bausch Health Companies
BHC
|
2.23 B | $ 4.99 | -2.35 % | $ 1.82 B | Canada |
 |
Harrow Health
HROW
|
31.8 M | $ 34.02 | 0.05 % | $ 1.25 B | USA |
 |
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
-25.2 M | $ 4.54 | -3.1 % | $ 293 M | USA |
 |
Pacira BioSciences
PCRX
|
5.41 M | $ 22.49 | -0.71 % | $ 1.04 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 5.8 | -1.02 % | $ 229 M | USA |
 |
Rockwell Medical
RMTI
|
-5.23 M | $ 1.03 | 0.98 % | $ 24 M | USA |
 |
Assertio Holdings
ASRT
|
8.47 M | $ 14.91 | 6.5 % | $ 95.5 M | USA |
 |
Canopy Growth Corporation
CGC
|
-95.6 M | $ 0.95 | -2.29 % | $ 102 M | Canada |
 |
Solid Biosciences
SLDB
|
-178 M | $ 6.87 | -3.78 % | $ 601 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.35 | -0.74 % | $ 402 M | Canada |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.35 | -1.1 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 2.42 | -5.1 % | $ 3 M | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
28.3 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.41 | -0.7 % | $ 3.96 B | Canada |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.9 | 3.23 % | $ 44.9 M | USA |
 |
TherapeuticsMD
TXMD
|
-7.6 M | $ 2.31 | - | $ 24.1 M | USA |
 |
Veru
VERU
|
-36.6 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Viatris
VTRS
|
3.51 B | $ 13.2 | -0.68 % | $ 15.8 B | USA |
 |
Organogenesis Holdings
ORGO
|
12.3 M | $ 2.42 | -2.23 % | $ 319 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-52.3 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
-785 M | $ 9.43 | -1.46 % | $ 1.31 B | USA |
 |
cbdMD
YCBD
|
-2.86 M | $ 0.76 | -1.19 % | $ 3.28 M | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |